Submitted:
06 July 2023
Posted:
10 July 2023
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Background and Related Works
2.1. Conventional Methods for Clinical Decision-Making
2.2. Studies on Patient Values and Their Relationships with Decision-Making
2.3. Literature Analysis Methods
3. Materials and Methods
3.1. An Overview of the Model
3.2. Collecting and Modeling Clinical Evidence
3.3. Value-based Medical Decision-Making and Treatment Plan Selection
3.4. A Unified Model for Decision Evidence
3.5. Population-Based Value Pre-Configuration
3.6. Recommendation Algorithm and Solution Output
| Algorithm 1 An algorithm for calculating the weight of treatment plans that integrates values through patient information and arguments. |
|
| Row | Step | Description |
|---|---|---|
| 1-4 | Step 1 | Input data: Patient’s objective symptoms (Patient_obj_symptoms), Patient’s values (Patient_values), Arguments database (Arguments), C:V ratio |
| 6-17 | Step 2 | Match patient’s objective symptoms with arguments: For each symptom in Patient_obj_symptoms, and for each argument in Arguments, check if the symptom matches the argument’s symptom. If yes, update the treatment weight of the argument based on its type (positive or negative) |
| 19-30 | Step 3 | Match patient’s values with arguments: For each value in Patient_values, and for each argument in Arguments, check if the value matches the argument’s value and if the symptom matches the argument’s symptom. If yes, update the treatment weight of the argument based on its type |
| 32-35 | Step 4 | Adjust treatment plan weights based on C:V ratio: For each treatment plan in Arguments, calculate the adjusted weight by combining the clinical weight and value weight according to the C:V ratio |
| 37-38 | Step 5 | Sort treatment plans by weight in descending order: Sort the treatment plans by weight in descending order |
| 40-43 | Step 6 | Output treatment plan weights and related arguments: Output the sorted treatment plans and their associated clinical and value-based arguments |
4. Experiment and Evaluation
4.1. Prototype System Implementation
4.2. Model Validation and Evaluation
4.3. Experimental Results
5. Discussion
6. Conclusion
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
Abbreviations
| CDSS | Clinical decision support systems |
| PROM | Patient-reported outcome measures |
| SDM | Shared decision making |
| NICE | National institute for health and care excellence |
| VBDE | Value-based decision evidence |
| UMDE | Unified model for decision evidence |
| RDF | Resource description framework |
| VICDS | Value-incorporated clinical decision system |
References
- Hibbard, J.H.; Greene, J. What The Evidence Shows About Patient Activation: Better Health Outcomes And Care Experiences; Fewer Data On Costs. Health Affairs 2013, 32, 207–214. [Google Scholar] [CrossRef] [PubMed]
- Greenhalgh, J.; Long, A.F.; Flynn, R. The use of patient reported outcome measures in routine clinical practice: lack of impact or lack of theory? Social Science & Medicine 2005, 60, 833–843. [Google Scholar] [CrossRef] [PubMed]
- Elwyn, G.; Frosch…, D. Shared Decision Making: A Model for Clinical Practice. Journal of General Internal Medicine 2012, 27, 1361–1367. [Google Scholar] [CrossRef]
- Torenholt, R.; Tjørnhøj-Thomsen, T. ‘Is this something I should be worried about?’: A study of nurses’ recontextualisation work when making clinical decisions based on patient reported outcome data. Social Science & Medicine 2022, 294, 114645. [Google Scholar]
- Sutton, D.R.; Fox, J. The syntax and semantics of the PROforma guideline modeling language. Journal of the American Medical Informatics Association 2003. [Google Scholar] [CrossRef] [PubMed]
- Brignardello-Petersen, R.; Carrasco-Labra, A.; Guyatt, G.H. How to Interpret and Use a Clinical Practice Guideline or Recommendation: Users’ Guides to the Medical Literature. JAMA 2021, 326, 1516–1523. [Google Scholar] [CrossRef] [PubMed]
- Parikh, S.; Goldstein, A.; Koenig, M.K.; Scaglia, F.; Enns, G.M.; Saneto, R.; Anselm, I.; Cohen, B.H.; Falk, M.J.; Greene, C. Diagnosis and management of mitochondrial disease: a consensus statement from the Mitochondrial Medicine Society. Genetics in Medicine Official Journal of the American College of Medical Genetics 2015. [Google Scholar] [CrossRef]
- Domain, M. decision support system for breast cancer treatment based on data mining technologies and clinical practice guidelines. 2005. [Google Scholar]
- Xiao, L.; Fox, J. Towards an Agent-Oriented Framework for Multidisciplinary Decision Support and Its Application to Triple Assessment of Breast Cancer. In Proceedings of the Computer Software & Applications Conference; 2017. [Google Scholar]
- Xiao, L.; Zhou, H.; Fox, J. Towards a systematic approach for argumentation, recommendation, and explanation in clinical decision support. Mathematical Biosciences and Engineering: MBE 2022, 19, 10445–10473. [Google Scholar] [CrossRef]
- Berry, A.B.; Lim, C.Y.; Hartzler, A.L.; Hirsch, T.; Ludman, E.; Wagner, E.H.; Ralston, J.D. "It’s good to know you’re not a stranger every time": Communication about Values Between Patients with Multiple Chronic Conditions and Healthcare Providers. Proceedings of the ACM on Human-Computer Interaction 2017, 1, 1–20. [Google Scholar] [CrossRef]
- Epstein, R.M.; Street, R.L. The values and value of patient-centered care. Annals of Family Medicine 2011, 9, 100–103. [Google Scholar] [CrossRef] [PubMed]
- Curtis, J.R.; Patrick, D.L.; Engelberg, R.A.; Norris, K.; Asp, C.; Byock, I. A measure of the quality of dying and death. Initial validation using after-death interviews with family members. Journal of Pain & Symptom Management 2002, 24, 17–31. [Google Scholar] [CrossRef]
- Wherton, J.; Sugarhood, P.; Procter…, R. Designing assisted living technologies ‘in the wild’: preliminary experiences with cultural probe methodology. BMC Medical Research Methodology,12,1(2012-12-20) 2012, 12, 188–188. [Google Scholar] [CrossRef] [PubMed]
- Liu, Z.; Xiao, L.; Chen, J.; Yu, H.; Ye, Y. An Emotion-fused Medical Knowledge Graph and its Application in Decision Support. In Proceedings of the 2022 IEEE 46th Annual Computers, , Software, and Applications Conference (COMPSAC); IEEE, 2022; pp. 1381–1388. [Google Scholar]
- Wu, C.; Xiao, L. Evidence based on patient’s experience data and clinical guidelines-for patient-oriented clinical decision support. In Proceedings of the 2021 International Conference on Public Health and Data Science (ICPHDS). IEEE; 2021; pp. 240–247. [Google Scholar]
- Yang, J.; Xiao, L.; Li, K. Modelling clinical experience data as an evidence for patient-oriented decision support. BMC Medical Informatics and Decision Making 2020, 20. [Google Scholar] [CrossRef] [PubMed]
- Porr, C.; Gaudine, A.; Woo, K.; Smith-Young, J.; Green, C. How community nurses manage ethical conflicts: A grounded theory study. Global Qualitative Nursing Research 2019, 6, 2333393619894958. [Google Scholar] [CrossRef]
- Hsieh, H.-F. Three Approaches to Qualitative Content Analysis. Qual Health Res 2005, 15, 1277–1288. [Google Scholar] [CrossRef]
- Sweileh, W.M.; Sawalha, A.F.; Al-Jabi, S.W.; Zyoud, S.H.; Shraim, N.Y.; Abu-Taha, A.S. A bibliometric analysis of literature on malaria vector resistance: (1996 – 2015). Globalization & Health 2016, 12, 76. [Google Scholar] [CrossRef]
- Durrani, S.; Heena, H. Controversies regarding ovarian suppression and infertility in early stage breast cancer. Cancer management and research 2020, 12, 813. [Google Scholar] [CrossRef]
- Castel, L.D.; Hartmann, K.E.; Mayer, I.A.; Saville, B.R.; Alvarez, J.; Boomershine, C.S.; Abramson, V.G.; Chakravarthy, A.B.; Friedman, D.L.; Cella, D.F. Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort. Cancer 2013, 119, 2375–2382. [Google Scholar] [CrossRef]
- Rachner, T.D.; Coleman, R.; Hadji, P.; Hofbauer, L.C. Bone health during endocrine therapy for cancer. The Lancet Diabetes & Endocrinology 2018, 6, 901–910. [Google Scholar]
- Jankowitz, R.C.; McGuire, K.P.; Davidson, N.E. Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer. The Breast 2013, 22, S165–S170. [Google Scholar] [CrossRef]
- Murray, J.; Miller, W.R.; Dixon, J.M. Neoadjuvant endocrine therapy models. Breast Cancer Research Protocols 2006, 489–502. [Google Scholar]
- New aromatase inhibitors for breast cancer. Drug and Therapeutics Bulletin 1997, 35, 55–56. [https://dtb.bmj.com/content/35/7/55.full.pdf]. [CrossRef] [PubMed]
- Kanti, V.; Nuwayhid, R.; Lindner, J.; Hillmann, K.; Bangemann, N.; Kleine-Tebbe, A.; Blume-Peytavi, U.; Garcia Bartels, N. Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients. Journal of the European Academy of Dermatology and Venereology 2016, 30, 112–118. [Google Scholar] [CrossRef] [PubMed]
- Reinert, T.; Gonçalves, R.; Ellis, M.J. Current status of neoadjuvant endocrine therapy in early stage breast cancer. Current Treatment Options in Oncology 2018, 19, 1–14. [Google Scholar] [CrossRef] [PubMed]
- Lima, M.T.M.; de Carvalho, K.P.; Mazzutti, F.S.; de Almeida Maia, M.; Canto, P.P.L.; Paiva, C.E.; de Paiva Maia, Y.C. Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients. BMC cancer 2017, 17, 1–11. [Google Scholar] [CrossRef]
- Desai, P.; Aggarwal, A. Breast cancer in women over 65 years-a review of screening and treatment options. Clinics in Geriatric Medicine 2021, 37, 611–623. [Google Scholar] [CrossRef]
- Brown, L.C.; Murphy, A.R.; Lalonde, C.S.; Subhedar, P.D.; Miller, A.H.; Stevens, J.S. Posttraumatic stress disorder and breast cancer: Risk factors and the role of inflammation and endocrine function. Cancer 2020, 126, 3181–3191. [Google Scholar] [CrossRef]
- Huang, Y.; Huang, X.; Huang, X.; Lin, S.; Luo, S.; Gu, D.; Weng, X.; Xu, X. Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer. Human Reproduction 2023, 38, 1099–1110. [Google Scholar] [CrossRef]
- Ellis, M.J.; Rigden, C.E. Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data. Current medical research and opinion 2006, 22, 2479–2487. [Google Scholar] [CrossRef]
- Lee, E.; Nelson, O.L.; Puyana, C.; Takita, C.; Wright, J.L.; Zhao, W.; Reis, I.M.; Lin, R.Y.; Hlaing, W.M.; Bakalar, J.L.; et al. Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study. Breast Cancer Research 2019, 21, 1–11. [Google Scholar] [CrossRef] [PubMed]
- Hodis, H.N.; Mack, W.J. Postmenopausal hormone therapy and cardiovascular disease in perspective. Clinical obstetrics and gynecology 2008, 51, 564. [Google Scholar] [CrossRef] [PubMed]











| Six categories values | Fine-grained values | Six categories values | Fine-grained values |
|---|---|---|---|
| Activities | fracture | Principles | independence |
| recurrence | treatment duration | ||
| traveling | confidence | ||
| reading | appearance | ||
| walking | weight | ||
| Abilities | survival | Emotions | risk |
| work | pregnancy | ||
| rest | exhaustion | ||
| talking | pain | ||
| vision | unbearable | ||
| convenience | depression | ||
| exercise | |||
| Possessions | convenience | Relationships | family |
| transportation | friend | ||
| expensive | colleague | ||
| cost effective | community |
| No. | Category | Keywords |
|---|---|---|
| 1 | Endocrine therapy | Hormone therapy |
| Tamoxifen | ||
| Aromatase inhibitors | ||
| Ovarian ablation/suppression | ||
| 2 | Radiotherapy | - |
| 3 | Chemotherapy | - |
| 4 | Surgery | Mastectomy |
| Breast reconstruction | ||
| Breast conservation | ||
| 5 | Targeted Therapy | - |
| 6 | Immunotherapy | - |
| 7 | Bisphosphonates | - |
| 8 | Complementary Therapy | - |
| Population features | Related | Side effects | Weight |
|---|---|---|---|
| Actor | Appearance, Temperament | Weight gain | 0.88 |
| Alopecia | 0.85 | ||
| Skin darkens | 0.74 | ||
| Diarrhea | 0.30 | ||
| Writer | Creativity, Spirit | Memory loss | 0.94 |
| Tremor | 0.87 | ||
| Insomnia | 0.81 | ||
| Fatigue | 0.67 | ||
| Assembly line worker | Work and rest, Repetitive work | Joint pain | 0.86 |
| Insomnia | 0.73 | ||
| Numbness in limbs | 0.70 | ||
| Back pain | 0.65 |
| Index | Author /Year | Title | Finding | Link Start with https://pubmed.ncbi.nlm.nih.gov/ |
|---|---|---|---|---|
| 1 | Durrani /2020 | Controversies Regarding Ovarian Suppression and Infertility in Early Stage Breast Cancer[21] | The main concern after adjuvant chemotherapy is the risk of losing fertility, as chemotherapy can induce early menopause in most premenopausal breast cancer patients. Tamoxifen only slightly increases the risk of early menopause. | 32104064/ |
| 2 | Castel / 2013 | Time course of arthralgia among women initiating aromatase inhibitor therapy and a postmenopausal comparison group in a prospective cohort[22] | Women undergoing endocrine therapy have more severe joint pain, and have more severe menopausal symptoms or existing joint-related diseases relative to before treatment. Joint pain is more severe than expected after menopause and often leads to reduced compliance. | 23575918/ |
| 3 | Rachner / 2018 | Bone health during endocrine therapy for cancer[23] | Common osteoporosis guidelines are likely to have underestimated the fracture risk of patients receiving endocrine therapy—especially in patients on aromatase inhibitor therapy. | 29572126/ |
| 4 | Jankowitz / 2013 | Optimal systemic therapy for premenopausal women with hormone receptor-positive breast cancer[24] | Chemotherapy has a shorter duration compared to endocrine therapy. | 26996100/ |
| 5 | Murray /2006 | Neoadjuvant endocrine therapy models[25] | Chemotherapy is more effective than endocrine therapy at shrinking the tumour | 16491621/ |
| 6 | Collier / 1997 | New aromatase inhibitors for breast cancer[26] | Endocrine therapy can provide self-administered oral medication, while chemotherapy requires injections at the hospital. | 9282426/ |
| 7 | Kanti / 2015 | Evaluation of trichodynia (hair pain) during chemotherapy or tamoxifen treatment in breast cancer patients[27] | Chemotherapy has more severe hair loss and scalp pain compared to Tamoxifen, and the duration is also longer. | 26403680/ |
| 8 | Reinert / 2018 | Current Status of Neoadjuvant Endocrine Therapy in Early Stage Breast Cancer[28] | Endocrine therapy is a practical, cost-effective treatment | 29663173/ |
| 9 | Lima / 2017 | Temporal influence of endocrine therapy with tamoxifen and chemotherapy on nutritional risk and obesity in breast cancer patients[29] | Women on endocrine therapy with TMX are mostly overweighed and obese, most evidently in women who received CT, and who were at the beginning of treatment. | 28851304/ |
| 10 | Desai / 2021 | Breast Cancer in Women Over 65 years- a Review of Screening and Treatment Options[30] | Primary endocrine therapy is a low-risk option for those with limited life expectancy. | /34600726/ |
| 11 | Brown / 2020 | Posttraumatic stress disorder and breast cancer: Risk factors and the role of inflammation and endocrine function[31] | Tamoxifen also has been shown to be involved in adverse mood reactions such as depression | 32374431/ |
| 12 | Huang / 2023 | Cost-effectiveness analysis of ovarian function preservation with GnRH agonist during chemotherapy in premenopausal women with early breast cancer[32] | GnRHa plus Chemo was a cost-effective strategy for premenopausal women with BC in the USA. | 37075316/ |
| 13 | Eills / 2006 | Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data[33] | For those with positive nodes, initiation of treatment with aromatase inhibitors may be beneficial to avoid tamoxifen-associated early relapses after diagnosis. | 17257462/ |
| 14 | Eills / 2006 | Initial versus sequential adjuvant aromatase inhibitor therapy: a review of the current data[33] | From an economic perspective, aromatase inhibitors are considered cost-effective compared to tamoxifen. | 17257462/ |
| 15 | Lee / 2019 | Association between C-reactive protein and radiotherapy-related pain in a tri-racial/ethnic population of breast cancer patients: a prospective cohort study[34] | In the postoperative radiotherapy process of obese patients, pain occurs, which has a negative impact on the quality of life. | 31138314/ |
| 16 | Hodis / 2008 | Postmenopausal hormone therapy and cardiovascular disease in perspective[35] | Hormone therapy after menopause can reduce the mortality rate and the risk of coronary heart disease. | 18677151/ |
| Index | Clinical condition | Value | Support | Oppose | Weight | Source in Table 3 |
|---|---|---|---|---|---|---|
| 1 | premenopausal | pregnancy later | Endocrine therapy | Chemotherapy | 2 | 1 |
| 2 | - | pain | - | Endocrine therapy | 2 | 2 |
| 3 | - | fracture | - | Endocrine therapy | 2 | 3 |
| 4 | ER+, pre-surgery |
treatment duration | Chemotherapy | Endocrine therapy | 2 | 4 |
| 5 | premenopausal | treatment outcome | Chemotherapy | Endocrine therapy | 3 | 5 |
| 6 | ER+, HER2- |
convenience | Endocrine therapy | Chemotherapy | 3 | 6 |
| 7 | - | appearance | Endocrine therapy | Chemotherapy | 2 | 7 |
| 8 | ER+, Grade 2 |
cost | Endocrine therapy | - | 2 | 8 |
| 9 | - | weight | - | Endocrine therapy | 2 | 9 |
| 10 | ER+, |
risk | - | Endocrine therapy | 2 | 10 |
| 11 | ER+ | depression | - | Endocrine therapy | 2 | 11 |
| 12 | age 18-49, premenopausal |
family cost effective |
Chemotherapy+ GnRHa |
Chemotherapy | 3 | 12 |
| 13 | node-positive | recurrence | Anastrozole | Tamoxifen | 2 | 13 |
| 14 | - | cost effective | Aromatase | Tamoxifen | 2 | 14 |
| 15 |
, after surgery, overweight |
pain | - | Radiotherapy | 2 | 15 |
| 16 | postmenopausal | mobility, survival | - | Hormone therapy | 2 | 16 |
| 17 | ER+ | risk | Endocrine therapy | Chemotherapy | 2 | 5 |
| Treatment | VICDS | GPT | Follow-up questions |
|---|---|---|---|
| Chemotherapy | 8 | 10 | 8 |
| Radiotherapy | 6 | 7 | 5 |
| Tamoxifen | 4 | 4 | 5 |
| Aromatase | 4 | 3 | 4 |
| Mastectomy | 2 | 2 | 3 |
| Targeted therapy | 4 | 2 | 3 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).